Case Study AOP 43: A Framework for Using Current (and Future) Assays for Predictive DART

> Todd Zurlinden, Ph.D. National Center for Computational Toxicology Office of Research and Development U.S. Environmental Protection Agency Research Triangle Park, NC

DART Mechanisms: Strategies to Target In Vitro and In Silico Models to Address Data and Assessment Needs


November 16, 2018

SEPA Current Testing Paradigm

- Traditional animal-based models for assessing prenatal developmental toxicity (OECD TG 414) expose pregnant rats and/or rabbits during organogenesis and necropsy at term.
- From the animal we get apical endpoints, i.e. skeletal malformation, visceral cleft, growth restrictions, etc.
 - Lack mechanistic depth and detail
 - Does not scale to the human exposure universe

SEPA Predictive DART


- How can mechanistic information support developmental hazard identification in a 3R's compliant manner?
- How can *in vitro* data and *in silico* models capture the relevant mechanistic information?
- What does this look like within the context of developmental vascular toxicity?



\$EPA

OECD Aop43: developmental vascular toxicity

Potential MIE Inhibition of VEGFR2 acts disrupts of vasculogenesis during development following several cell and tissuebased key events





SOURCE: Knudsen and Kleinstreuer (2011) Birth Defects Res – AOP 43



OECD Aop43: developmental vascular toxicity

The synthetic thalidomide analog 5HPP-33 may disrupt angiogenesis through several possible AOPs.






SOURCE: Knudsen and Kleinstreuer (2011) Birth Defects Res – AOP 43



Molecular Initiating Event (MIE)

candidate


Utilize high throughput so



Validating angiogenic cycle key events




EPA




TBXA2

FGFR1









Angiogenesis

Remodeling

Utilize cell-based assays across multiple angiogenic effects to quantitate cellular key events


G

DUIT CV

ISV

- Tubule formation and network formation Α.
- Tubulogenesis in high throughput screening Β.
- Endothelial network formation in co-culture C.
- nuCTNB and endothelial migration D.
- Endothelial cell migration assay Ε.
- 3D angiogenic sprouting F.
- KDR-reporter transgenic zebrafish embryos G.


SEPA *In vitro* confirmation of *in silico* prediction



A pVDC ToxPi

- B HUVEC tubulogenesis (FICAM)
- C HUVEC tubulogenesis (NCATS)
- D tubulogenesis in synthetic matrices (HMAPS)
- E tubulogenesis in Matrigel (HMAPS)
- F nuCTNB biomarker (VALA)
- G endothelial cell migration (VALA)
- H iPSC endothelial sprouting (HMAPS)
- ISV reporter zebrafish (NHEERL)
- J reporter zebrafish (UDUBLIN)
- K HUVEC tubulogenesis (VALA)
- L ANY (B to K)


Tissue-level key events and embryotoxicity



Todd Zurlinden - NCCT

SEPA


W Murphy, W Daly, G Kaushick – U Wisconsin (HMAPS)



SOURCE: Knudsen and Kleinstreuer (2011) Birth Defects Res – AOP 43

EPA Current (and future) assays

- Establish suite of gene targets from the literature potentially resulting in angiogenic disruption
 - Organize as MIEs within context of AOP network
- Use ToxCast HTS assays to determine how a chemical enters the AOP
- Validate cellular-level effect through suite of assays corresponding to different parts of the angiogenic cycle
- Predict system dynamics for test compound and similar compounds using HTS data and OCM and agent-based modes for cell-cell interactions





Thank You

Questions?